Apr 17, 2024

7 Things to Know about GLP-1s like Semaglutide

7 Things to Know about GLP-1s like Semaglutide



When considering GLP-1 receptor agonists like semaglutide or tirzepatide for weight loss, here are 7 factors to take into account:

  1. Efficacy in Weight Loss: GLP-1 receptor agonists have shown significant efficacy in promoting weight loss in obese individuals. Semaglutide and tirzepatide, in particular, have demonstrated substantial weight reduction in clinical trials, making them promising options for weight management in this population.

  2. Mechanism of Action: Understand the mechanism by which GLP-1 receptor agonists induce weight loss. These medications work by reducing appetite, increasing feelings of fullness, and slowing gastric emptying, which collectively contribute to calorie restriction and weight loss.

  3. Comorbidity Management: Consider the impact of weight loss on obesity-related comorbidities. Beyond improving glycemic control, GLP-1 receptor agonists have been associated with improvements in cardiovascular risk factors, such as blood pressure, lipid levels, and markers of inflammation, which are crucial for managing obesity-related complications.

  4. Adherence and Tolerance: Evaluate the patient's ability to adhere to and tolerate GLP-1 receptor agonist therapy. Nausea, vomiting, and gastrointestinal disturbances are common side effects, particularly during the initial weeks of treatment. However, these symptoms often subside with continued use, and dose titration may help improve tolerability.

  5. Multifaceted Benefits: Highlight the multifaceted benefits of GLP-1 receptor agonists beyond weight loss. These medications offer advantages such as improved glycemic control, reduced cardiovascular risk, and potential preservation of beta-cell function, making them valuable therapeutic options for obese individuals with type 2 diabetes.

  6. Individualized Treatment: Tailor treatment plans to the individual needs and preferences of the patient. Consider factors such as baseline weight, metabolic profile, existing co-morbidities, and treatment goals when selecting the most suitable GLP-1 receptor agonist and dosing regimen.

  7. Long-term Management: Develop a comprehensive long-term management strategy. Weight management is a lifelong endeavor, and sustained adherence to lifestyle modifications, including diet and physical activity, is essential for maintaining weight loss achieved with GLP-1 receptor agonists.

By addressing these key considerations, healthcare providers can effectively incorporate GLP-1 receptor agonists into the treatment plan for weight loss, harnessing the benefits while optimizing overall health outcomes.

FWD Care, Inc.™ is a patient management platform that collaborates with independent physicians and other practitioners delivering services through the FWD Care, Inc™ infrastructure. FWD Care, Inc.™ does not directly offer medical or pharmacy services, and a payment does not assure the prescription will be written or dispensed. Medical services are rendered by independent providers. The information on this website is for educational purposes only and is not a replacement for professional medical advice, diagnosis, or treatment. If you have health-related questions or concerns, please consult your doctor. This website is an advertisement for services, not for any specific medication.*Disclaimer: FDA-approved medications like Saxenda®, Victoza®, Wegovy®, and Ozempic® are proprietary to Novo Nordisk™, while Mounjaro™ is a product of Eli Lilly and Company™. FWD Care, Inc.™ is not associated with or endorsed by these companies or their products. We do not supply these medications. Individuals interested in these products should consult with their licensed healthcare provider or pharmacist.

© 2024 FWD Care, Inc. All Rights Reserved.